6533b839fe1ef96bd12a5a39

RESEARCH PRODUCT

Emerging Roles of RNA 3′-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders

Stefano SpadaSven DanckwardtJamie Nourse

subject

0301 basic medicinePolyadenylationcardiovascular disorderslcsh:QR1-502ReviewComputational biologyBiologyPolyadenylationCleavage (embryo)Biochemistrylcsh:MicrobiologyTranscriptome03 medical and health sciences0302 clinical medicineTranscription (biology)NeoplasmsGene expressionHumansDirectionalitycancerheterocyclic compoundsEpigeneticsMolecular BiologyRNA Cleavagediseasetherapyalternative polyadenylationRNAfood and beveragesNeurodegenerative Diseases3′ end processing030104 developmental biologyCardiovascular Diseases030220 oncology & carcinogenesisneurodegenerative disorderscardiovascular systemRNAbiomarkercleavage and polyadenylation

description

A crucial feature of gene expression involves RNA processing to produce 3′ ends through a process termed 3′ end cleavage and polyadenylation (CPA). This ensures the nascent RNA molecule can exit the nucleus and be translated to ultimately give rise to a protein which can execute a function. Further, alternative polyadenylation (APA) can produce distinct transcript isoforms, profoundly expanding the complexity of the transcriptome. CPA is carried out by multi-component protein complexes interacting with multiple RNA motifs and is tightly coupled to transcription, other steps of RNA processing, and even epigenetic modifications. CPA and APA contribute to the maintenance of a multitude of diverse physiological processes. It is therefore not surprising that disruptions of CPA and APA can lead to devastating disorders. Here, we review potential CPA and APA mechanisms involving both loss and gain of function that can have tremendous impacts on health and disease. Ultimately we highlight the emerging diagnostic and therapeutic potential CPA and APA offer.

10.3390/biom10060915https://www.mdpi.com/2218-273X/10/6/915